MediciNova Inc (MNOV) News Headlines

▮ More

Date

Headline

1/5/2023 10:36:27 PM MediciNova To Meet With FDA To Discuss Clinical Development Of Parenteral Formulation Of MN-166

4/11/2022 6:37:42 AM MediciNova Announces Plans For Phase 2 Trial Of MN-001 In NAFLD With Type 2 Diabetes Mellitus And Hypertriglyceridemia

2/1/2022 6:38:01 AM MediciNova Gets New Patent Covering MN-001 For Hypertriglyceridemia, Hypercholesterolemia, Hyperlipoproteinemia In Korea

11/24/2021 7:14:14 AM Pre-market Movers: OCUP, KTTA, GAME, BIOL, JWN…

6/21/2021 6:53:26 AM MediciNova Reports Positive Results In Phase 2 Trial Of MN-166 In Alcohol Use Disorder - Quick Facts

6/21/2021 6:35:33 AM MediciNova Announces Positive Results From Phase 2 Trial Of MN-166 In Alcohol Use Disorder

3/9/2021 5:42:22 PM MediciNova Partners With BARDA To Develop Chlorine Gas-induced Lung Injury Treatment; Stock Surges

3/4/2021 2:21:01 AM KMPH Scores FDA Nod For ADHD Drug, MNOV Quits COVID-19 Vaccine Race, UTHR Gives Up On Trevyent

3/28/2018 8:34:02 PM B. Riley FBR Starts MediciNova Inc (MNOV) At Buy With $22 Price Target

Older Articles

Medicinova Inc (MNOV)